The European Organization for the Research and Treatment of Cancer (EORTC) has developed a commonly used validated questionnaire specific to anal cancer (EORTC QLQ-ANL27). It is used as an adjunct to the core EORTC quality-of-life (QoL) questionnaire QLQ-C30. This validated questionnaire was not available in any Indian language, and therefore, Indian patients not familiar with English could not fill it. We aimed to translate and validate the EORTC QLQ-ANL27 module in Hindi, Marathi, and Bangla languages. This study was conducted in the Department of Radiation Oncology at the Tata Memorial Hospital, a tertiary cancer center in Mumbai, India, from September 01, 2022, to March 31, 2023. The QLQ-ANL27 questionnaire was translated into Hindi, Marathi, and Bangla languages using the standard EORTC guidelines. The overall process comprised two independent forward translations of the original English questionnaire into the target languages, followed by reconciliation between the two forward translations. The reconciled version was then back translated to English. The report generated was sent to the EORTC translation unit (TU) for review. Once approved by the EORTC TU, these translated versions were pilot tested on 30 patients (10 for each language) with cancer of the rectum or anal canal. After responding to the questionnaires, each patient was individually interviewed to explore any difficulty encountered while answering the QoL questionnaire. The interviewer specifically asked whether the patients found any words or sentences difficult to answer, confusing, or upsetting, and for suggestions on better phrasing. The EORTC QLQ-ANL27 was translated to Hindi, Marathi, and Bangla, followed by back translation into English within a period of 2 months between September 2022 and October 2022. The translated versions were approved by the EORTC TU in October 2022. Validation of the translated versions was conducted between December 2022 and March 2023 in 30 patients diagnosed with anorectal cancer. The median age of the patients was 55 (interquartile range, 29–77); the male-to-female ratio was 2:1. There were no suggestions or doubts in the Hindi, Marathi, and Bangla questionnaires during the pilot testing. After reviewing the pilot testing reports, the EORTC TU approved the translated versions of QLQ-ANL27. The reliability of the translated questionnaires was confirmed using Cronbach’s alpha, which were 0.838, 0.743, and 0.808 for the Hindi, Marathi, and Bangla versions, respectively. The Hindi, Marathi, and Bangla translations of the QLQ-ANL27 module have been validated and approved by the EORTC and are now available for use (Clinical Trials Registry-India, CTRI/2022/12/047970).
{"title":"Translation and validation of the Hindi, Marathi, and Bangla versions of the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire: Anal Cancer (QLQ-ANL27) module: A prospective cohort study","authors":"R. Krishnatry, Revathy Krishnamurthy, Purva Pawar, Devankshi Rane, Debanjan Chakraborty, Debanjali Datta, Sayan Das, Utpal Gaikwad, Aasma Siddiqui, Suman Ghosh, Akanksha Anup, Tejaswi Ambre, Shivkumar Gudi, Reena Engineer","doi":"10.4103/crst.crst_217_23","DOIUrl":"https://doi.org/10.4103/crst.crst_217_23","url":null,"abstract":"\u0000 \u0000 \u0000 The European Organization for the Research and Treatment of Cancer (EORTC) has developed a commonly used validated questionnaire specific to anal cancer (EORTC QLQ-ANL27). It is used as an adjunct to the core EORTC quality-of-life (QoL) questionnaire QLQ-C30. This validated questionnaire was not available in any Indian language, and therefore, Indian patients not familiar with English could not fill it.\u0000 \u0000 \u0000 \u0000 We aimed to translate and validate the EORTC QLQ-ANL27 module in Hindi, Marathi, and Bangla languages.\u0000 \u0000 \u0000 \u0000 This study was conducted in the Department of Radiation Oncology at the Tata Memorial Hospital, a tertiary cancer center in Mumbai, India, from September 01, 2022, to March 31, 2023. The QLQ-ANL27 questionnaire was translated into Hindi, Marathi, and Bangla languages using the standard EORTC guidelines. The overall process comprised two independent forward translations of the original English questionnaire into the target languages, followed by reconciliation between the two forward translations. The reconciled version was then back translated to English. The report generated was sent to the EORTC translation unit (TU) for review. Once approved by the EORTC TU, these translated versions were pilot tested on 30 patients (10 for each language) with cancer of the rectum or anal canal. After responding to the questionnaires, each patient was individually interviewed to explore any difficulty encountered while answering the QoL questionnaire. The interviewer specifically asked whether the patients found any words or sentences difficult to answer, confusing, or upsetting, and for suggestions on better phrasing.\u0000 \u0000 \u0000 \u0000 The EORTC QLQ-ANL27 was translated to Hindi, Marathi, and Bangla, followed by back translation into English within a period of 2 months between September 2022 and October 2022. The translated versions were approved by the EORTC TU in October 2022. Validation of the translated versions was conducted between December 2022 and March 2023 in 30 patients diagnosed with anorectal cancer. The median age of the patients was 55 (interquartile range, 29–77); the male-to-female ratio was 2:1. There were no suggestions or doubts in the Hindi, Marathi, and Bangla questionnaires during the pilot testing. After reviewing the pilot testing reports, the EORTC TU approved the translated versions of QLQ-ANL27. The reliability of the translated questionnaires was confirmed using Cronbach’s alpha, which were 0.838, 0.743, and 0.808 for the Hindi, Marathi, and Bangla versions, respectively.\u0000 \u0000 \u0000 \u0000 The Hindi, Marathi, and Bangla translations of the QLQ-ANL27 module have been validated and approved by the EORTC and are now available for use (Clinical Trials Registry-India, CTRI/2022/12/047970).\u0000","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"35 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139814796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The European Organization for the Research and Treatment of Cancer (EORTC) has developed a commonly used validated questionnaire specific to anal cancer (EORTC QLQ-ANL27). It is used as an adjunct to the core EORTC quality-of-life (QoL) questionnaire QLQ-C30. This validated questionnaire was not available in any Indian language, and therefore, Indian patients not familiar with English could not fill it. We aimed to translate and validate the EORTC QLQ-ANL27 module in Hindi, Marathi, and Bangla languages. This study was conducted in the Department of Radiation Oncology at the Tata Memorial Hospital, a tertiary cancer center in Mumbai, India, from September 01, 2022, to March 31, 2023. The QLQ-ANL27 questionnaire was translated into Hindi, Marathi, and Bangla languages using the standard EORTC guidelines. The overall process comprised two independent forward translations of the original English questionnaire into the target languages, followed by reconciliation between the two forward translations. The reconciled version was then back translated to English. The report generated was sent to the EORTC translation unit (TU) for review. Once approved by the EORTC TU, these translated versions were pilot tested on 30 patients (10 for each language) with cancer of the rectum or anal canal. After responding to the questionnaires, each patient was individually interviewed to explore any difficulty encountered while answering the QoL questionnaire. The interviewer specifically asked whether the patients found any words or sentences difficult to answer, confusing, or upsetting, and for suggestions on better phrasing. The EORTC QLQ-ANL27 was translated to Hindi, Marathi, and Bangla, followed by back translation into English within a period of 2 months between September 2022 and October 2022. The translated versions were approved by the EORTC TU in October 2022. Validation of the translated versions was conducted between December 2022 and March 2023 in 30 patients diagnosed with anorectal cancer. The median age of the patients was 55 (interquartile range, 29–77); the male-to-female ratio was 2:1. There were no suggestions or doubts in the Hindi, Marathi, and Bangla questionnaires during the pilot testing. After reviewing the pilot testing reports, the EORTC TU approved the translated versions of QLQ-ANL27. The reliability of the translated questionnaires was confirmed using Cronbach’s alpha, which were 0.838, 0.743, and 0.808 for the Hindi, Marathi, and Bangla versions, respectively. The Hindi, Marathi, and Bangla translations of the QLQ-ANL27 module have been validated and approved by the EORTC and are now available for use (Clinical Trials Registry-India, CTRI/2022/12/047970).
{"title":"Translation and validation of the Hindi, Marathi, and Bangla versions of the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire: Anal Cancer (QLQ-ANL27) module: A prospective cohort study","authors":"R. Krishnatry, Revathy Krishnamurthy, Purva Pawar, Devankshi Rane, Debanjan Chakraborty, Debanjali Datta, Sayan Das, Utpal Gaikwad, Aasma Siddiqui, Suman Ghosh, Akanksha Anup, Tejaswi Ambre, Shivkumar Gudi, Reena Engineer","doi":"10.4103/crst.crst_217_23","DOIUrl":"https://doi.org/10.4103/crst.crst_217_23","url":null,"abstract":"\u0000 \u0000 \u0000 The European Organization for the Research and Treatment of Cancer (EORTC) has developed a commonly used validated questionnaire specific to anal cancer (EORTC QLQ-ANL27). It is used as an adjunct to the core EORTC quality-of-life (QoL) questionnaire QLQ-C30. This validated questionnaire was not available in any Indian language, and therefore, Indian patients not familiar with English could not fill it.\u0000 \u0000 \u0000 \u0000 We aimed to translate and validate the EORTC QLQ-ANL27 module in Hindi, Marathi, and Bangla languages.\u0000 \u0000 \u0000 \u0000 This study was conducted in the Department of Radiation Oncology at the Tata Memorial Hospital, a tertiary cancer center in Mumbai, India, from September 01, 2022, to March 31, 2023. The QLQ-ANL27 questionnaire was translated into Hindi, Marathi, and Bangla languages using the standard EORTC guidelines. The overall process comprised two independent forward translations of the original English questionnaire into the target languages, followed by reconciliation between the two forward translations. The reconciled version was then back translated to English. The report generated was sent to the EORTC translation unit (TU) for review. Once approved by the EORTC TU, these translated versions were pilot tested on 30 patients (10 for each language) with cancer of the rectum or anal canal. After responding to the questionnaires, each patient was individually interviewed to explore any difficulty encountered while answering the QoL questionnaire. The interviewer specifically asked whether the patients found any words or sentences difficult to answer, confusing, or upsetting, and for suggestions on better phrasing.\u0000 \u0000 \u0000 \u0000 The EORTC QLQ-ANL27 was translated to Hindi, Marathi, and Bangla, followed by back translation into English within a period of 2 months between September 2022 and October 2022. The translated versions were approved by the EORTC TU in October 2022. Validation of the translated versions was conducted between December 2022 and March 2023 in 30 patients diagnosed with anorectal cancer. The median age of the patients was 55 (interquartile range, 29–77); the male-to-female ratio was 2:1. There were no suggestions or doubts in the Hindi, Marathi, and Bangla questionnaires during the pilot testing. After reviewing the pilot testing reports, the EORTC TU approved the translated versions of QLQ-ANL27. The reliability of the translated questionnaires was confirmed using Cronbach’s alpha, which were 0.838, 0.743, and 0.808 for the Hindi, Marathi, and Bangla versions, respectively.\u0000 \u0000 \u0000 \u0000 The Hindi, Marathi, and Bangla translations of the QLQ-ANL27 module have been validated and approved by the EORTC and are now available for use (Clinical Trials Registry-India, CTRI/2022/12/047970).\u0000","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"41 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139874501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_201_23
J. Ghosh, S. Ganguly
{"title":"Pathological complete response in breast cancer: Is it truly a surrogate for outcome?","authors":"J. Ghosh, S. Ganguly","doi":"10.4103/crst.crst_201_23","DOIUrl":"https://doi.org/10.4103/crst.crst_201_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"32 1","pages":"232 - 234"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81668083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sabse bada kaun - Me or “C”?","authors":"Vandana N. Mahajan","doi":"10.4103/crst.crst_28_23","DOIUrl":"https://doi.org/10.4103/crst.crst_28_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"19 1","pages":"285 - 285"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82248514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_138_23
P. Balakrishnan, V. Sharmila
{"title":"Spontaneous expulsion of a huge hemorrhagic cervical leiomyoma: A rare case report","authors":"P. Balakrishnan, V. Sharmila","doi":"10.4103/crst.crst_138_23","DOIUrl":"https://doi.org/10.4103/crst.crst_138_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"31 1","pages":"357 - 359"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89946185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_177_23
Purvish M. Parikh, V. Talwar, Monu Goyal
{"title":"Authors' reply to Sathe et al., Cherulil et al., Vaishya et al., and Gupta et al.","authors":"Purvish M. Parikh, V. Talwar, Monu Goyal","doi":"10.4103/crst.crst_177_23","DOIUrl":"https://doi.org/10.4103/crst.crst_177_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"1 1","pages":"338 - 340"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78329846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_174_23
P. Patil
{"title":"Improving outcomes for colorectal cancer in India: Time to take the first step!","authors":"P. Patil","doi":"10.4103/crst.crst_174_23","DOIUrl":"https://doi.org/10.4103/crst.crst_174_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"22 1","pages":"328 - 329"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82143383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ehsan Ulhaq, Febin Huda, C. Suhail, H. Sheth, R. Anu
The field of oncology has made great strides in the last decade. There have been tremendous advancements in precision oncology and cutting-edge diagnostics to match the unprecedented rise in the incidence of cancer globally. Hereditary cancer syndromes which account for between 5-10% of the total cancer burden, occupy a novel niche, offering the opportunity to receive an early diagnosis through targeted surveillance, adopt preventive screening measures, and preemptively control the disease. To prepare this review, we searched in PubMed, international government web pages, and the National Comprehensive Cancer Network guidelines for published literature on genetic testing in hereditary cancers. This review article represents a consensus between the authors, based on the literature review, with a view to being relevant in the Indian setting. Genetic counseling plays a pivotal role in the diagnosis and management of hereditary cancers. India must adopt a streamlined approach to the treatment of hereditary cancers by enhancing awareness and incorporating the right protocols for genetic counseling. This educational series, focused on genetic counseling for hereditary and sporadic cancers, is the first step in generating awareness among individuals and clinicians in India.
{"title":"Narrative review on genetic counseling for hereditary cancers: General considerations","authors":"Ehsan Ulhaq, Febin Huda, C. Suhail, H. Sheth, R. Anu","doi":"10.4103/crst.crst_16_23","DOIUrl":"https://doi.org/10.4103/crst.crst_16_23","url":null,"abstract":"The field of oncology has made great strides in the last decade. There have been tremendous advancements in precision oncology and cutting-edge diagnostics to match the unprecedented rise in the incidence of cancer globally. Hereditary cancer syndromes which account for between 5-10% of the total cancer burden, occupy a novel niche, offering the opportunity to receive an early diagnosis through targeted surveillance, adopt preventive screening measures, and preemptively control the disease. To prepare this review, we searched in PubMed, international government web pages, and the National Comprehensive Cancer Network guidelines for published literature on genetic testing in hereditary cancers. This review article represents a consensus between the authors, based on the literature review, with a view to being relevant in the Indian setting. Genetic counseling plays a pivotal role in the diagnosis and management of hereditary cancers. India must adopt a streamlined approach to the treatment of hereditary cancers by enhancing awareness and incorporating the right protocols for genetic counseling. This educational series, focused on genetic counseling for hereditary and sporadic cancers, is the first step in generating awareness among individuals and clinicians in India.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"30 1","pages":"239 - 247"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82659738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_183_23
Mehdi Mahmoodkhani, Mehdi Shafiei, M. Sharifi, A. Naeimi, D. Tehrani
{"title":"Authors' reply to Patel and Lucke-Wold","authors":"Mehdi Mahmoodkhani, Mehdi Shafiei, M. Sharifi, A. Naeimi, D. Tehrani","doi":"10.4103/crst.crst_183_23","DOIUrl":"https://doi.org/10.4103/crst.crst_183_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"23 1","pages":"332 - 333"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88496982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：